Sofinnova secures €82M for early-stage medtech startups

Sofinnova Partners has closed its fourth medtech fund at €82 million, exceeding its target to support early-stage medical-device startups in Europe. The fund’s size makes it one of the more notable raises in the sector this year, particularly at a time when many venture funds are struggling to meet their goals.

The fund’s oversubscription highlights a persistent interest in medtech, a sector that has faced challenges in recent years. While other areas of healthcare have attracted more attention, medtech remains a complex and capital-intensive space, often requiring specialized investors. Sofinnova’s focus on pre-clinical, pre-revenue startups means its backers are placing bets on the firm’s ability to identify promising companies early, before clinical data is available.

The €82 million figure provides a snapshot of European venture activity. Other recent fund closes, such as Connect Ventures’ partial raise for its deeptech fund, suggest a cautious environment. In contrast, Sofinnova’s full close stands out, though it remains smaller than some other recent raises, like DTCP’s €455 million defence tech fund. The fund’s size aligns with typical Series A rounds in medtech, where €5-10 million checks are common. The raise also indicates that some investors are still willing to support niche strategies if the firm has a track record of execution.

It remains uncertain whether this fund signals broader trends or is an exception. The European Investment Fund recently backed WAD Capital’s debut fund, but that was a generalist vehicle. Medtech-focused funds are less common, and Sofinnova’s success may reflect its established position rather than a shift in investor appetite. The coming months will show whether other firms can replicate this outcome or if this remains an isolated case.

For startups, the fund offers a dedicated source of early-stage capital, though competition for funding will likely be high. Sofinnova’s model is selective, prioritizing teams with deep technical and regulatory expertise. The oversubscription may also mean that startups without a clear path to clinical validation could face challenges in securing support.

The fund’s timing coincides with a slowdown in medtech acquisitions, as larger companies focus on financial performance. This dynamic increases pressure on startups to raise follow-on funding, making early-stage capital even more critical. While Sofinnova’s fund won’t resolve these challenges, it provides a rare funding option for startups that are too early for growth-stage investors and too specialized for generalists. Whether this will be enough to sustain the sector’s pipeline remains to be seen. For now, the oversubscription offers a sign of continued interest in medtech.

Sources: tech.eu